UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038956
Receipt number R000044134
Scientific Title A Study on the Effect of Plant Extract on Postprandial Blood Glucose and Serum Triglyceride -A Randomized, Double-blind, Placebo-controlled, Cross-over Study-
Date of disclosure of the study information 2020/01/05
Last modified on 2023/12/07 10:28:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study on the Effect of Plant Extract on Postprandial Blood Glucose and Serum Triglyceride
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-

Acronym

A Study on the Effect of Plant Extract on Postprandial Blood Glucose and Serum Triglyceride

Scientific Title

A Study on the Effect of Plant Extract on Postprandial Blood Glucose and Serum Triglyceride
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-

Scientific Title:Acronym

A Study on the Effect of Plant Extract on Postprandial Blood Glucose and Serum Triglyceride

Region

Japan


Condition

Condition

No (include borderline diabetes)

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm the effect of plant extract on postprandial blood glucose and serum triglyceride

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood glucose AUC and Serum triglyceride AUC

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Powder containing plant extract, 1 sachet per serving

Interventions/Control_2

Powder not containing plant extract, 1 sachet per serving

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Healthy males and females aged 20 to 64 year-old.
(2) Subjects who have enough information about its objective and details, can make self-judgment and voluntarily give written informed consent before they agree to participate.
(3) Subjects who can obey the directions of the investigators.

Key exclusion criteria

(1) Subjects whose fasting blood glucose level is 126 mg/dL and over or two-hour blood glucose level after 75 g glucose loading is 200 mg/dL and over and/or who have been diagnosed with diabetes.
(2) Subjects whose fasting serum triglyceride level is 45 mg/dL or less and 150 mg/dL or over, or casual serum triglyceride level is 650 mg/dL and over.
(3) Subjects who contract or are under treatment for serious diseases (e.g., diabetes, liver disease, kidney disease, digestive system disease, heart disease, respiratory disease, peripheral vascular disorder, etc.).
(4) Subjects who use oral medication affecting blood glucose or lipid metabolism.
(5) Subjects who constantly use supplements and/or functional foods (including Food for Specified Health Uses, Foods with Functional Claims) affecting blood glucose or lipid metabolism.
(6) Subjects with abnormal parameters in liver and/or kidney function.
(7) Subjects who have a history of digestive disease surgery.
(8) Subjects with a disease that may have an influence on this study currently under treatment.
(9) Subjects who have declared an allergic reaction to test foods, or loading foods.
(10) Subjects with anemia or who have difficulty with self blood collection.
(11) Subjects who play high intensity sports and/or are on a diet.
(12) Subjects with irregular life patterns.
(13) Subjects who use medicines (including OTC and/or prescribed medications) continuously.
(14) Subjects who drink excessive alcohol, or who can't stop drinking from one day before each measurement.
(15) Subjects who are planning to become pregnant after informed consent for the current study or are pregnant or lactating.
(16) Subjects who are planning to participate in other clinical studies.
(17) Subjects who are judged as unsuitable for the study by the investigator for other reasons.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Shinichiro
Middle name
Last name Takashima

Organization

TOYO SHINYAKU Co., Ltd.

Division name

Clinical and analytical research center

Zip code

841-0005

Address

7-28 Yayoigaoka, Tosu-Shi, Saga, Japan

TEL

0942-81-3555

Email

takashimas@toyoshinyaku.co.jp


Public contact

Name of contact person

1st name Nobutaka
Middle name
Last name Kusaba

Organization

TOYO SHINYAKU Co., Ltd.

Division name

Clinical and analytical research center

Zip code

841-0005

Address

7-28 Yayoigaoka, Tosu-Shi, Saga, Japan

TEL

0942-81-3555

Homepage URL


Email

gakujutsu@toyoshinyaku.co.jp


Sponsor or person

Institute

TOYO SHINYAKU Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

TOYO SHINYAKU Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Miura Clinic, Medical Corporation Kanonkai IRB

Address

9F Higashitenma building, 1-7-17 Higashitenma, Kita-ku, Osaka, Osaka, Japan

Tel

06-6135-5200

Email

mterashima@miura-cl.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 01 Month 05 Day


Related information

URL releasing protocol

http://www.pieronline.jp/content/article/0386-3603/48060/1065

Publication of results

Published


Result

URL related to results and publications

http://www.pieronline.jp/content/article/0386-3603/48060/1065

Number of participants that the trial has enrolled

20

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results

2020 Year 06 Month 30 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 10 Month 30 Day

Date of IRB

2019 Year 11 Month 21 Day

Anticipated trial start date

2020 Year 01 Month 06 Day

Last follow-up date

2020 Year 03 Month 10 Day

Date of closure to data entry

2020 Year 03 Month 12 Day

Date trial data considered complete

2020 Year 03 Month 13 Day

Date analysis concluded

2020 Year 04 Month 10 Day


Other

Other related information



Management information

Registered date

2019 Year 12 Month 23 Day

Last modified on

2023 Year 12 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044134


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name